J2 Capital Management Inc Invests $492,000 in Johnson & Johnson $JNJ

J2 Capital Management Inc purchased a new position in shares of Johnson & Johnson (NYSE:JNJ) during the second quarter, HoldingsChannel reports. The firm purchased 3,221 shares of the company’s stock, valued at approximately $492,000.

A number of other institutional investors and hedge funds have also made changes to their positions in JNJ. Highline Wealth Partners LLC grew its position in Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after buying an additional 86 shares during the period. Stone House Investment Management LLC acquired a new position in Johnson & Johnson during the first quarter worth about $47,000. 1248 Management LLC acquired a new position in Johnson & Johnson during the first quarter worth about $48,000. von Borstel & Associates Inc. acquired a new position in Johnson & Johnson during the first quarter worth about $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in Johnson & Johnson during the first quarter worth about $52,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $188.51 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The company has a market capitalization of $453.98 billion, a price-to-earnings ratio of 20.16, a PEG ratio of 2.37 and a beta of 0.40. The company’s 50 day simple moving average is $176.18 and its 200 day simple moving average is $162.83. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $189.78.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were given a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.8%. Johnson & Johnson’s dividend payout ratio is 55.61%.

Wall Street Analyst Weigh In

Several brokerages have weighed in on JNJ. Morgan Stanley upped their target price on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 17th. Erste Group Bank raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Wednesday, July 23rd. Barclays upped their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a report on Thursday, July 17th. Citigroup upped their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “buy” rating in a report on Thursday, August 21st. Finally, UBS Group set a $198.00 price target on shares of Johnson & Johnson in a report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $187.47.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.